SynthesisInfectious diseases and therapy2026
Burden of Respiratory Syncytial Virus Infection in Immunocompromised Adults: A Systematic Review of the Evidence From High-Income Countries.
Synthesis in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Individuals with immunocompromising conditions or receiving immunosuppressive therapy are at increased risk for severe outcomes and complications from respiratory syncytial virus (RSV). An in-depth systematic investigation into severe RSV disease among immunocompromised adults is lacking. We therefore performed this systematic literature review to summarize the literature (2000-2024) on the burden of RSV disease across a broad spectrum of immunocompromising conditions in adults residing in high-income countries, in terms of the incidence of RSV infection and the prevalence of hospitalizations, complications, and mortality among RSV-infected individuals. Relevant English-language articles were retrieved through PubMed and Embase searches. We included 36 articles in our review. All but four studies were conducted in Europe or the USA. Most evaluated solid organ transplant recipients (n = 11, including 8 evaluating lung transplants) or hematopoietic stem cell transplant recipients (n = 17). Our review shows that, in most studies, substantial proportions of RSV-infected immunocompromised adults required hospitalization (37.5-87.5% in lung transplant, 37.7-68.0% in any solid organ transplant, and 30.3-83.9% in stem cell transplant recipients), intensive care unit admission (11.7% in lung, 3.9-17.9% in any solid organ, and 4.8-29.8% in stem cell transplant recipients), and mechanical ventilation (0.0-10.4% in lung, 3.9-14.3% in any solid organ, and 2.7-29.8% in stem cell transplant recipients). Data from the identified articles indicate that in solid organ (especially lung) and stem cell transplant patients, the degree of immunosuppression-determined by anti-rejection regimens, corticosteroid dosing, and other adjunctive agents-may be an important determinant of the risk of RSV. Our review confirms that RSV poses a significant burden on immunocompromised adults, emphasizing the need to implement preventive strategies such as vaccination in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.